No Data
Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating
Insider Sale: Chief Business & Strat Officer of $APLS (APLS) Sells 1,235 Shares
Express News | RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $26 Price Target
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $31 to $47
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $32 to $60
Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes